Overall rank by patents
#29,556
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 9 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C22C (ALLOYS).
The verdict
Novelis holds 9 US patents across 9 technology areas, rank #29,556 of 50,000 tracked assignees.
Novelis Koblenz Gmbh has been granted 9 US utility patents between 2022 and 2025, placing Novelis Koblenz Gmbh at rank #29,556 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.9 claims per patent with primary concentration in C22C (ALLOYS). As a Foreign Corporation, Novelis Koblenz Gmbh is one of the more focused assignees in the PatentsView dataset. By volume, Novelis sits between Noster Inc. (9 patents, rank #29,552) and Nrgtek, Inc. (9 patents, rank #29,560) - the closest US assignees by grant volume. The composite Innovation Score of 48.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Novelis Koblenz Gmbh's 16.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novelis Koblenz Gmbh against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NOSTER INC.
9 patents
NOV CANADA ULC
9 patents
NOVARTIS TIERGESUNDHEIT AG
9 patents
NOVATION IQ LLC
9 patents
NOVOGY, INC.
9 patents
NOWWW.US Pty Ltd.
9 patents
NPC ROBOTICS CORPORATION
9 patents
NRGTEK, Inc.
9 patents
NOVELIS KOBLENZ GMBH
9 patents
What this shows Novelis holds 9 patents at rank #29,556, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,556 in granted patent volume.
Other assignees with the most granted patents in Novelis's primary technology class.
Novelis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 11.1% |
| 2024 | 6 | 66.7% |
| 2025 | 2 | 22.2% |
Top 9 of 9 technology areas
Overall rank by patents
#29,556
Across all tracked assignees
48.7 out of 100
How to use this portfolio
Novelis's 9 grants land it in the top 16% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.